Global Blood Plasma Market 2019-2027: Approval of Immunoglobulin-Centered Therapies -

DUBLIN--()--The "Global Blood Plasma Market 2019-2027" report has been added to's offering.

Global market for blood plasma is expected to display a positive market trend over the forecast period of 2019-2027, exhibiting a CAGR of 6.13%.

Plasma, the principal constituent of blood, plays a pivotal role in regulating the body's functions. It is composed of various useful elements, such as immunoglobulins, coagulation factors, albumin and protease inhibitors. Since insufficiencies in a component can give rise to disease, both basic and targeted research & development has begun in this field.

Blood plasma is part of an effective therapeutic plan of treatment in numerous therapies due to its potential in combatting several diseases, like leukemia, hemophilia, immunodeficiency and other bleeding diseases, which are chronic and life-threatening. Blood plasma products have proven to be a blessing for patients suffering from such conditions, which has demanded a more comprehensive knowledge of their applications.

Factors like surge in the treatment for hemophilia, expansion in indication into new therapeutic areas, rise in the geriatric population and the approval of immunoglobulin-centered therapies are driving the growth of the blood plasma market. On the other hand, the easy availability of recombinant plasma and the high costs of blood plasma treatments are obstructing the growth of the market.

Opportunities such as an increase in public awareness, rise in the cases of hemophilia and the rising number of opportunities can be leveraged by the market to reach the estimated growth. However, the high regulations in the market and the spread of pathogenic contaminants are some of the key challenges facing the market that need to be overcome.

Regional Outlook

The global blood plasma market spans across the regions of North America, the Middle East and Africa, Latin America, Europe and the Asia-Pacific. The Asia-Pacific blood plasma market was the fastest growing market over the world, in terms of CAGR.

The APAC region offers extensive opportunities for the expansion of the blood plasma market. The Asia-Pacific Blood Network (APBN) is a non-profit organization with strategic leadership policies for the regulation of its members' activities, in a bid to increase the plasma supply across the region. Established in 2006, the network aims to provide the safe, steady and cost-efficient supply of blood and its components.

Japan has dominated the Asia-Pacific market due to the rise in the number of its organizations that ensure the supply of blood plasma. China was second in significant contributions to the blood plasma market, as the limited availability of domestic plasma has hampered the overall yield.

Competitive Outlook

The companies that have been mentioned in the market report are Cerus Corp., General Electric, Co., China Biologic Products, Inc., ADMA Biologics, Inc., CSL Ltd., Biotest AG, Grifols International S.A., Baxter International, Inc., Octapharma AG, Arthrex and Shire Plc.

Biotest AG is an international company that supplies plasma protein & biotherapeutic drugs and manufactures products used in various therapeutic disciplines including clinical immunology, hematology and intensive care medicine. The company has achieved expertise in the production of immunoglobulins, clotting factors and albumin, along with monoclonal antibodies used in clinical development.

Key Topics Covered:

1. Global Blood Plasma Market - Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter's Five Forces Outlook

2.3. Vendor Scorecard

2.4. Clinical Guidelines

2.5. Regulation in the Plasma Therapeutics

2.6. Key Insights

2.7. Regulatory Outlook

2.8. Market Trends

2.9. Patent Outlook

2.10. Market Drivers

2.10.1. Expansion in Indication for New Therapeutic Areas

2.10.2. Approval of Immunoglobulin-Centered Therapies

2.10.3. Surge in the Hemophilia Treatment

2.10.4. Rise in the Elderly Population

2.11. Market Restraints

2.11.1. High Costs of Blood Plasma Treatments

2.11.2. Easy Availability of Recombinant Plasma

2.12. Market Opportunities

2.12.1. Increasing Public Cognizance

2.12.2. Rise in the Plasma-Derived Products Opportunities

2.12.3. Increasing Occurrence of Hemophilia

2.13. Market Challenges

2.13.1. Spread of Pathogenic Contaminants

2.13.2. High Regulations in the Market

2.14. Blood Plasma Industry by Mode of Delivery

2.14.1. Infusion Solutions

2.14.2. Gels

2.14.3. Sprays

2.14.4. Biomedical Sealants

3. Blood Plasma Market Outlook - by Blood Type

3.1. Albumin

3.2. Immunoglobulin

3.2.1. Intravenous Immunoglobulin

3.2.2. Subcutaneous Immunoglobulin

3.2.3. Other Immunoglobulin Type

3.3. Coagulation Factor Concentrates

3.4. Hyperimmunes

3.5. Other Plasma Fractionation Products

4. Blood Plasma Market Outlook - by Application

4.1. Oncology

4.2. Hematology

4.3. Transplantation

4.4. Rheumatology

4.5. Neurology

4.6. Immunology

4.7. Pulmonology

4.8. Other Applications

5. Blood Plasma Market Outlook - by End-User

5.1. Academic Institutions

5.2. Research Laboratories

5.3. Hospitals and Clinics

6. Blood Plasma Market - Regional Outlook

7. Company Profiles

7.1. Shire plc

7.2. Arthrex

7.3. Octapharma AG

7.4. Baxter International, Inc.

7.5. Grifols International S.A.

7.6. Biotest AG

7.7. Csl Ltd.

7.8. Adma Biologics, Inc.

7.9. China Biologic Products, Inc.

7.10. General Electric Co.

7.11. Cerus Corp.

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900